Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin versus placebo for non-alcoholic fatty liver disease
IRCT20140430017505N2Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatotic liver disease (MASLD) comparing Sitagliptin with Placebo (2 arms). Primary endpoint: Improvement of steatosis status. Started Feb 2019; status: completed.
02
Drugs
sitagliptin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT20140430017505N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140430017505N2.